English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Innovent Biologics, Inc.
Press release submission
| Jul 3, 2022
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
Press release submission
| Mar 20, 2019
INNOVENT BIOLOGICS, INC. : Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody
Press release submission
| Feb 27, 2019
INNOVENT BIOLOGICS, INC.: First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma
Trending
+
Technology/Innovation
Patient Daily
| May 8, 2025
Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+
Technology/Innovation
Patient Daily
| May 7, 2025
OTO Forum 2025 highlights innovation in ENT
+
Pharmaceuticals
Patient Daily
| May 8, 2025
Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+
Pharmaceuticals
Patient Daily
| May 8, 2025
National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments
